Huw Morris

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2006607/publications.pdf

Version: 2024-02-01

246 papers	24,672 citations	14655 66 h-index	8866 145 g-index
266 all docs	266 docs citations	266 times ranked	27265 citing authors

#	Article	IF	Citations
1	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.8	42
2	Decision-making, attitudes, and understanding among patients and relatives invited to undergo genome sequencing in the 100,000 Genomes Project: A multisite survey study. Genetics in Medicine, 2022, 24, 61-74.	2.4	7
3	Multi-modality machine learning predicting Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 35.	5.3	44
4	Elevated 4Râ€tau in astrocytes from asymptomatic carriers of the MAPT 10+16 intronic mutation. Journal of Cellular and Molecular Medicine, 2022, 26, 1327-1331.	3.6	6
5	A data-driven model of brain volume changes in progressive supranuclear palsy. Brain Communications, 2022, 4, .	3.3	12
6	Combining biomarkers for prognostic modelling of Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 707-715.	1.9	9
7	236â€... Systemic mitochondrial dysfunction in monogenic Parkinsonâ€™s disease as a potential biomarker for stratification. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A81.3-A81.	1.9	0
8	228â€... Testing shortened versions of smell tests to screen for hyposmia in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A79.2-A79.	1.9	0
9	The Impact of Type 2 Diabetes in Parkinson's Disease. Movement Disorders, 2022, 37, 1612-1623.	3.9	30
10	Diagnosing Premotor Multiple System Atrophy. Neurology, 2022, 99, .	1.1	4
11	Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Neuron, 2021, 109, 448-460.e4.	8.1	56
12	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
13	Genomeâ€Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Movement Disorders, 2021, 36, 424-433.	3.9	101
14	Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinsonâ€™s disease. Neurobiology of Aging, 2021, 97, 148.e17-148.e24.	3.1	16
15	Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes. Neurology: Genetics, 2021, 7, e557.	1.9	25
16	Assessing the relationship between monoallelic PRKN mutations and Parkinsonâ€™s risk. Human Molecular Genetics, 2021, 30, 78-86.	2.9	36
17	Sequence of clinical and neurodegeneration events in Parkinsonâ€™s disease progression. Brain, 2021, 144, 975-988.	7.6	49
18	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198

#	Article	IF	Citations
19	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
20	Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinsonâ€™s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The â€˜Exenatide-PD3â€™ study. BMJ Open, 2021, 11, e047993.	1.9	32
21	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
22	Whole-genome sequencing. Practical Neurology, 2021, 21, 322-327.	1.1	3
23	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	2.4	6
24	Comparison between four published definitions of hyposmia in Parkinson's disease. Brain and Behavior, 2021, 11, e2258.	2.2	4
25	Progress towards therapies for disease modification in Parkinson's disease. Lancet Neurology, The, 2021, 20, 559-572.	10.2	136
26	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nature Medicine, 2021, 27, 1451-1457.	30.7	63
27	Longitudinal risk factors for developing depressive symptoms in Parkinson's disease. Journal of the Neurological Sciences, 2021, 429, 117615.	0.6	5
28	A Modified Progressive Supranuclear Palsy Rating Scale. Movement Disorders, 2021, 36, 1203-1215.	3.9	13
29	The PINK1â€”Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells. PLoS ONE, 2021, 16, e0259903.	2.5	8
30	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
31	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
32	Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 377.	9.0	94
33	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
34	Plasma glial fibrillary acidic protein and neurofilament light chain, but not tau, are biomarkers of sports-related mild traumatic brain injury. Brain Communications, 2020, 2, fcaa137.	3.3	22
35	Making neurogenetics a global endeavour. Brain, 2020, 143, 1970-1973.	7.6	0
36	Investigation of Somatic Mutations in Human Brains Targeting Genes Associated With Parkinson's Disease. Frontiers in Neurology, 2020, 11, 570424.	2.4	8

#	Article	IF	Citations
37	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
38	Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain, 2020, 143, 2771-2787.	7.6	50
39	Identification of UBAP1 mutations in juvenile hereditary spastic paraplegia in the 100,000 Genomes Project. European Journal of Human Genetics, 2020, 28, 1763-1768.	2.8	9
40	Revisiting the assessment of tremor: clinical review. British Journal of General Practice, 2020, 70, 611-614.	1.4	3
41	Investigating the contribution of an intronic variation at the trim11 locus to pathological and clinical heterogeneity in progressive supranuclear palsy. Alzheimer's and Dementia, 2020, 16, e042936.	0.8	0
42	ATP10B and the risk for Parkinsonâ€™s disease. Acta Neuropathologica, 2020, 140, 401-402.	7.7	14
43	Pathogenetic insights into young-onset Parkinson disease. Nature Reviews Neurology, 2020, 16, 245-246.	10.1	4
44	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry,the, 2020, 7, 875-882.	7.4	1,005
45	Genomeâ€Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor. Movement Disorders, 2020, 35, 705-707.	3.9	7
46	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
47	Testing Shortened Versions of Smell Tests to Screen for Hyposmia in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 394-398.	1.5	11
48	Automated Brainstem Segmentation Detects Differential Involvement in Atypical Parkinsonian Syndromes. Journal of Movement Disorders, 2020, 13, 39-46.	1.3	16
49	<scp>LRRK</scp> 2 activation controls the repair of damaged endomembranes in macrophages. EMBO Journal, 2020, 39, e104494.	7.8	116
50	The genetic and clinicoâ€pathological profile of earlyâ€onset progressive supranuclear palsy. Movement Disorders, 2019, 34, 1307-1314.	3.9	16
51	Genetic analysis of Mendelian mutations in a large UK population-based Parkinsonâ€™s disease study. Brain, 2019, 142, 2828-2844.	7.6	62
52	The Parkinson's Disease Mendelian Randomization Research Portal. Movement Disorders, 2019, 34, 1864-1872.	3.9	50
53	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
54	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47

#	Article	IF	Citations
55	MAPT p.V363I mutation. Neurology: Genetics, 2019, 5, e347.	1.9	10
56	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
57	The long-term outcome of impulsive compulsive behaviours in Parkinsonâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1288-1289.	1.9	3
58	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
59	Neural correlates of early cognitive dysfunction in Parkinson's disease. Annals of Clinical and Translational Neurology, 2019, 6, 902-912.	3.7	17
60	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
61	A novel TBK1 mutation in a family with diverse frontotemporal dementia spectrum disorders. Journal of Physical Education and Sports Management, 2019, 5, a003913.	1.2	19
62	L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism and Related Disorders, 2019, 65, 55-61.	2.2	14
63	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	5.3	83
64	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
65	Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 768-773.	1.9	29
66	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
67	REM sleep behaviour disorder: an early window for prevention in neurodegeneration?. Brain, 2019, 142, 498-501.	7.6	16
68	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	30.7	111
69	Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuoâ€perceptual deficits. Movement Disorders, 2018, 33, 544-553.	3.9	25
70	Features of GBA-associated Parkinsonâ€™s disease at presentation in the UK Tracking Parkinsonâ€™s study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 702-709.	1.9	103
71	Developing and validating Parkinsonâ€™s disease subtypes and their motor and cognitive progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1279-1287.	1.9	116
72	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15

#	Article	IF	Citations
73	Verbal adynamia in parkinsonian syndromes: behavioral correlates and neuroanatomical substrate. Neurocase, 2018, 24, 204-212.	0.6	19
74	Chaperone-mediated autophagy as a therapeutic target for Parkinson disease. Expert Opinion on Therapeutic Targets, 2018, 22, 823-832.	3.4	31
75	Sensitivity and Specificity of the ECAS in Parkinsonâ€™s Disease and Progressive Supranuclear Palsy. Parkinson's Disease, 2018, 2018, 1-8.	1.1	11
76	Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurology, 2018, 75, 1416.	9.0	66
77	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
78	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
79	Small spiral, big mass. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1189-1190.	1.9	0
80	Can neuroimaging predict dementia in Parkinsonâ€™s disease?. Brain, 2018, 141, 2545-2560.	7.6	46
81	A detailed clinical study of pain in 1957 participants with early/moderate Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 27-32.	2.2	77
82	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	1.9	107
83	Discovery and functional prioritization of Parkinsonâ€™s disease candidate genes from large-scale whole exome sequencing. Genome Biology, 2017, 18, 22.	8.8	96
84	Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics. Parkinsonism and Related Disorders, 2017, 37, 65-71.	2.2	34
85	Clinical Features and Differential Diagnosis of Parkinsonâ€™s Disease. , 2017, , 103-115.		5
86	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. Acta Neuropathologica, 2017, 133, 337-352.	7.7	193
87	Utility of the new Movement Disorder Society clinical diagnostic criteria for Parkinson's disease applied retrospectively in a large cohort study of recent onset cases. Parkinsonism and Related Disorders, 2017, 40, 40-46.	2.2	15
88	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
89	John Stuart Morris. BMJ: British Medical Journal, 2017, 357, j1748.	2.3	0
90	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402

#	Article	IF	Citations
91	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
92	Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases. JAMA Neurology, 2017, 74, 780.	9.0	245
93	Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 883-888.	1.9	26
94	The Catsâ€andâ€Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease. Movement Disorders, 2017, 32, 1789-1790.	3.9	26
95	Reply: MRI findings of visual system alterations in Parkinsonâ€™s disease. Brain, 2017, 140, e70-e70.	7.6	0
96	Establishing the role of rare coding variants in known Parkinson's disease risk loci. Neurobiology of Aging, 2017, 59, 220.e11-220.e18.	3.1	15
97	Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study. Movement Disorders Clinical Practice, 2017, 4, 509-516.	1.5	35
98	BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open, 2017, 7, e017990.	1.9	9
99	[P1â€“258]: THE PROSPECT STUDY: DEVELOPMENT OF A UKâ€BASED LONGITUDINAL OBSERVATIONAL STUDY OF PSP, CBD, MSA AND ATYPICAL PARKINSONISM SYNDROMES. Alzheimer's and Dementia, 2017, 13, P348.	0.8	1
100	[O4â€“02â€“01]: PLASMA AND CSF LEVELS OF NEUROFILAMENT LIGHT CHAIN CORRELATE IN ATYPICAL PARKINSONIAN SYNDROMES AND DISTINGUISH THEM FROM PARKINSON's AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1228.	0.8	0
101	Excessive burden of lysosomal storage disorder gene variants in Parkinsonâ€™s disease. Brain, 2017, 140, 3191-3203.	7.6	323
102	Early Onset Parkinsonâ€™s Disease in a family of Moroccan origin caused by a p.A217D mutation in PINK1: a case report. BMC Neurology, 2017, 17, 153.	1.8	3
103	1115â€…Chronic traumatic encephalopathy in retired footballers with dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A1.1-A1.	1.9	0
104	Variation in Recent Onset Parkinsonâ€™s Disease: Implications for Prodromal Detection. Journal of Parkinson's Disease, 2016, 6, 289-300.	2.8	21
105	Functional Magnetic Resonance Imaging Neurofeedback-guided Motor Imagery Training and Motor Training for Parkinsonâ€™s Disease: Randomized Trial. Frontiers in Behavioral Neuroscience, 2016, 10, 111.	2.0	49
106	Update on fluid biomarkers for concussion. Concussion, 2016, 1, CNC12.	1.0	11
107	Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1183-1190.	1.9	24
108	Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 33, 96-101.	2.2	46

#	Article	IF	Citations
109	Psychiatric disorders, myoclonus dystonia and <scp>SGCE</scp> : an international study. Annals of Clinical and Translational Neurology, 2016, 3, 4-11.	3.7	43
110	Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options. Current Treatment Options in Neurology, 2016, 18, 42.	1.8	63
111	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
112	Rare variants analysis of cutaneous malignant melanoma genes in Parkinson's disease. Neurobiology of Aging, 2016, 48, 222.e1-222.e7.	3.1	19
113	Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Movement Disorders, 2016, 31, 1518-1526.	3.9	128
114	Visual dysfunction in Parkinsonâ€™s disease. Brain, 2016, 139, 2827-2843.	7.6	320
115	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	7.6	170
116	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
117	Additional rare variant analysis in Parkinsonâ€™s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Human Molecular Genetics, 2016, 25, ddw348.	2.9	48
118	EFFECTS OF VASCULAR COMORBIDITY IN PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.13-e1.	1.9	0
119	DEEP PHENOTYPING OF THE G2019S LRRK2 MUTATION IN PARKINSON'S DISEASE: UCL COHORT. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.16-e1.	1.9	0
120	CHANGE IN VISUAL FUNCTION IN PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.18-e1.	1.9	0
121	PARKINSON'S FAMILIES PROJECT: RECRUITMENT OF FAMILIAL PD PATIENTS VIA THE BNSU. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.20-e1.	1.9	0
122	CORTICOBASAL SYNDROME AND CORTICOBASAL DEGENERATION. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.9-e1.	1.9	0
123	Increased fractional anisotropy in the motor tracts of Parkinson's disease suggests compensatory neuroplasticity or selective neurodegeneration. European Radiology, 2016, 26, 3327-3335.	4.5	94
124	Olfaction inParkinsingle and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica, 2016, 134, 271-276.	2.1	21
125	Distal hereditary motor neuropathy with vocal cord paresis: from difficulty in choral singing to a molecular genetic diagnosis. Practical Neurology, 2016, 16, 247-251.	1.1	9
126	Is the MC1R variant p.R160W associated with Parkinson's?. Annals of Neurology, 2016, 79, 159-161.	5.3	18

#	Article	IF	Citations
127	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
128	Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Molecular Neurodegeneration, 2015, 10, 41.	10.8	90
129	Tracking Parkinsonâ€™s: Study Design and Baseline Patient Data. Journal of Parkinson's Disease, 2015, 5, 947-959.	2.8	64
130	Precompetitive Data Sharing as a Catalyst toÂAddress Unmet Needs in Parkinsonâ€™s Disease 1. Journal of Parkinson's Disease, 2015, 5, 581-594.	2.8	25
131	A Missense Mutation in KCTD17 Causes Autosomal Dominant Myoclonus-Dystonia. American Journal of Human Genetics, 2015, 96, 938-947.	6.2	109
132	CHCHD2 and Parkinson's disease. Lancet Neurology, The, 2015, 14, 678-679.	10.2	50
133	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
134	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22
135	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
136	Defining neurodegeneration on <scp>G</scp>uam by targeted genomic sequencing. Annals of Neurology, 2015, 77, 458-468.	5.3	63
137	Polygenic risk of <scp>P</scp>arkinson disease is correlated with disease age at onset. Annals of Neurology, 2015, 77, 582-591.	5.3	115
138	Genetic risk and age in Parkinson's disease: Continuum not stratum. Movement Disorders, 2015, 30, 850-854.	3.9	71
139	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
140	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	10.2	179
141	Parkinson's disease: chameleons and mimics. Practical Neurology, 2015, 15, 14-25.	1.1	61
142	SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. Journal of Neurology, 2014, 261, 2296-2304.	3.6	59
143	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2014, 23, 562-562.	2.9	5
144	Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. Neurobiology of Aging, 2014, 35, 1512.e5-1512.e10.	3.1	28

#	Article	IF	Citations
145	SGCZ mutations are unlikely to be associated with myoclonus dystonia. Neuroscience, 2014, 272, 88-91.	2.3	2
146	Recent advances in Parkinsonâ€™s disease genetics. Journal of Neurology, 2014, 261, 259-266.	3.6	65
147	Genetic comorbidities in Parkinson's disease. Human Molecular Genetics, 2014, 23, 831-841.	2.9	57
148	Benign hereditary chorea related to <scp>NKX</scp>2.1: expansion of the genotypic and phenotypic spectrum. Developmental Medicine and Child Neurology, 2014, 56, 642-648.	2.1	49
149	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
150	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
151	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
152	Reduced C9orf72 protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 1779.e5-1779.e13.	3.1	234
153	Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurology, 2013, 70, 1268-76.	9.0	51
154	Exome sequencing expands the mutational spectrum of SPG8 in a family with spasticity responsive to l-DOPA treatment. Journal of Neurology, 2013, 260, 2414-2416.	3.6	18
155	The frequency of spinocerebellar ataxia type 23 in a UK population. Journal of Neurology, 2013, 260, 856-859.	3.6	12
156	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	2.8	79
157	Variation in tau isoform expression in different brain regions and disease states. Neurobiology of Aging, 2013, 34, 1922.e7-1922.e12.	3.1	49
158	SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain, 2013, 136, 294-303.	7.6	91
159	Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology, 2013, 80, 2042-2048.	1.1	129
160	BNSU SURVEILLANCE PROJECT: MYOCLONUS DYSTONIA SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.184-e2.	1.9	0
161	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2013, 22, 1696-1696.	2.9	3
162	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122

#	Article	IF	Citations
163	FAMILY HISTORY IN YOUNG ONSET PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.69-e2.	1.9	0
164	DISTAL SPINAL MUSCULAR ATROPHY WITH VOCAL PARESIS: FROM THE WELSH CHOIR TO GENES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.117-e2.	1.9	0
165	TRACKING PARKINSON'S (THE PROBAND STUDY)â€“INTERIM REPORT FROM THE FIRST 1000 CASES. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.70-e2.	1.9	0
166	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2013, 22, 2973-2973.	2.9	0
167	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	2.9	176
168	1624â€...Myoclonus dystonia: a clinical and genetic description: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.146-e1.	1.9	0
169	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
170	Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiology of Aging, 2012, 33, 838.e7-838.e11.	3.1	23
171	Systematic Review and UKâ€Based Study of PARK2 (parkin), PINK1, PARK7 (DJâ€1) and LRRK2 in earlyâ€onset Parkinson's disease. Movement Disorders, 2012, 27, 1522-1529.	3.9	141
172	Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research. PLoS ONE, 2012, 7, e43099.	2.5	44
173	C9ORF72 expansion in amyotrophic lateral sclerosis/frontotemporal dementia also causes parkinsonism. Movement Disorders, 2012, 27, 1072-1074.	3.9	45
174	Recent Advances in the Genetics of the ALS-FTLD Complex. Current Neurology and Neuroscience Reports, 2012, 12, 243-250.	4.2	50
175	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
176	Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson's Disease. PLoS ONE, 2012, 7, e28787.	2.5	21
177	A novel presenilin 1 mutation, I202F occurring at a previously predicted pathogenic site causing autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2011, 32, 556.e1-556.e2.	3.1	6
178	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
179	Familial frontotemporal dementia with amyotrophic lateral sclerosis and a shared haplotype on chromosomeÂ9p. Journal of Neurology, 2011, 258, 647-655.	3.6	76
180	The motor phenotype of Parkinson's disease in relation to age at onset. Movement Disorders, 2011, 26, 457-463.	3.9	122

#	Article	IF	Citations
181	Quality of life in youngâ€•compared with lateâ€•onset Parkinson's disease. Movement Disorders, 2011, 26, 2011-2018.	3.9	63
182	Psychiatric disorders, myoclonus dystonia, and the epsilonâ€•sarcoglycan gene: A systematic review. Movement Disorders, 2011, 26, 1939-1942.	3.9	41
183	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Human Molecular Genetics, 2011, 20, 345-353.	2.9	202
184	Hyposmia in progressive supranuclear palsy. Movement Disorders, 2010, 25, 570-577.	3.9	43
185	Perry syndrome due to the DCTN1 G71R mutation: A distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure. Movement Disorders, 2010, 25, 767-770.	3.9	41
186	POMD03 Association of head injury with Parkinson's disease risk by age at onset. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e58-e58.	1.9	1
187	POMD10 Do psychiatric disorders form part of the myoclonus-dystonia syndrome phenotype? A systematic review of published literature. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e59-e60.	1.9	0
188	Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology, 2010, 75, 367-372.	1.1	40
189	PATH42 Lineage, clinical, genetic, structural and cellular characterisation of a novel epilepsy mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e19-e19.	1.9	0
190	Familial early onset frontotemporal dementia caused by a novel S356T MAPT mutation, initially diagnosed as schizophrenia. Clinical Neurology and Neurosurgery, 2010, 112, 917-920.	1.4	37
191	Client and therapist views on exercise programmes for early-mid stage Parkinson's disease and Huntington's disease. Disability and Rehabilitation, 2010, 32, 917-928.	1.8	75
192	Prevalence and age of onset of Parkinson's disease in Cardiff: a community based cross sectional study and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 805-807.	1.9	89
193	Parkinâ€•related disease clinically diagnosed as a pallidoâ€•pyramidal syndrome. Movement Disorders, 2009, 24, 138-140.	3.9	9
194	Clinical and genetic characteristics of nonâ€•Asian dentatorubralâ€•pallidoluysian atrophy: A systematic review. Movement Disorders, 2009, 24, 1636-1640.	3.9	54
195	The genetic aetiology of late-onset chronic progressive cerebellar ataxia. Journal of Neurology, 2009, 256, 343-348.	3.6	25
196	The effect of onset age on the clinical features of Parkinsonâ€™s disease. European Journal of Neurology, 2009, 16, 450-456.	3.3	151
197	The effect of age and the H1c MAPT haplotype on MAPT expression in human brain. Neurobiology of Aging, 2009, 30, 1652-1656.	3.1	21
198	Dentatorubral pallidoluysian atrophy in South Wales. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 804-807.	1.9	22

#	Article	IF	Citations
199	Association, expression, pathobiology. Neurology, 2008, 71, 11-12.	1.1	0
200	Analysis of copy number variation using quantitative interspecies competitive PCR. Nucleic Acids Research, 2008, 36, e112-e112.	14.5	9
201	Clinical skills evaluation of trainees in a neurology department. Clinical Medicine, 2007, 7, 365-369.	1.9	26
202	Case control analysis of repeat expansion size in ataxia. Neuroscience Letters, 2007, 429, 28-32.	2.1	14
203	Autosomal dominant Parkinsonâ€™s disease and the route to new therapies. Expert Review of Neurotherapeutics, 2007, 7, 649-656.	2.8	2
204	Aripiprazole associated with severe exacerbation of Parkinson's disease. Movement Disorders, 2006, 21, 1538-1539.	3.9	43
205	Clinical grand round: A rapidly progressive pyramidal and extrapyramidal syndrome with a supranuclear gaze palsy. Movement Disorders, 2005, 20, 826-831.	3.9	5
206	Young onset limb spasticity with PSP-like brain and spinal cord NFT-tau pathology. Neurology, 2005, 64, 731-733.	1.1	6
207	Genetics of Parkinson's disease. Annals of Medicine, 2005, 37, 86-96.	3.8	67
208	Genome-Wide Analysis of the Parkinsonism-Dementia Complex of Guam. Archives of Neurology, 2004, 61, 1889-97.	4.5	44
209	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. American Journal of Medical Genetics Part A, 2004, 125B, 79-82.	2.4	24
210	Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology, 2003, 61, 102-104.	1.1	86
211	Strong association of the Saitohin gene Q7 variant with progressive supranuclear palsy. Neurology, 2003, 61, 407-409.	1.1	27
212	Sequence analysis of tau in familial and sporadic progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 388-390.	1.9	17
213	Neuropathologic variation in frontotemporal dementia due to the intronic tau 10 ⁺¹⁶ mutation. Neurology, 2002, 58, 1169-1175.	1.1	49
214	Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997â€“2000. Neurology, 2002, 59, 1121-1121.	1.1	28
215	Analysis of tau haplotypes in Pickâ€™s disease. Neurology, 2002, 59, 443-445.	1.1	50
216	Clinical features of frontotemporal dementia due to the intronic tau 10 ⁺¹⁶ mutation. Neurology, 2002, 58, 1161-1168.	1.1	85

#	Article	IF	Citations
217	Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain, 2002, 125, 969-975.	7.6	80
218	The parkinsonism dementia complex of Guam and flying foxes. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2002, , 12-12.	0.1	0
219	The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain, 2001, 124, 1438-1449.	7.6	226
220	No pathogenic mutations in the synphilin-1 gene in Parkinson's disease. Neuroscience Letters, 2001, 307, 125-127.	2.1	18
221	Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neuroscience Letters, 2001, 311, 145-148.	2.1	49
222	Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neuroscience Letters, 2001, 312, 118-120.	2.1	26
223	A clinical and pathological study of motor neurone disease on Guam. Brain, 2001, 124, 2215-2222.	7.6	39
224	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	3.9	6
225	Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology, 2001, 56, 1702-1706.	1.1	392
226	The Genetic and Pathological Classification of Familial Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1813.	4.5	114
227	Sign language tics in a prelingually deaf man. Movement Disorders, 2000, 15, 318-320.	3.9	19
228	Reply. Movement Disorders, 2000, 15, 587-588.	3.9	2
229	Multiple system atrophy/progressive supranuclear palsy: Î±-Synuclein, synphilin, tau, and APOE. Neurology, 2000, 55, 1918-1920.	1.1	82
230	Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology, 2000, 54, 697-697.	1.1	401
231	Clinical genetics of familial progressive supranuclear palsy. Brain, 1999, 122, 1233-1245.	7.6	124
232	The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 665-667.	1.9	103
233	Late onset startle induced tics. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 67, 782-784.	1.9	37
234	Progressive supranuclear palsy (Steele-Richardson-Olszewski disease). Postgraduate Medical Journal, 1999, 75, 579-584.	1.8	35

#	Article	IF	Citations
235	Use of corticosteroids to suppress drug toxicity in complicated tuberculosis. Journal of Infection, 1999, 39, 237-240.	3.3	6
236	Mutation in thetau exon 10 splice site region in familial frontotemporal dementia. Annals of Neurology, 1999, 45, 270-271.	5.3	43
237	Primary antiphospholipid syndrome presenting as a corticobasal degeneration syndrome. Movement Disorders, 1999, 14, 530-532.	3.9	21
238	Neurofibrillary tangle parkinsonian disorders?tau pathology andtau genetics. Movement Disorders, 1999, 14, 731-736.	3.9	40
239	Late-onset cytoplasmic body myopathy resembling myotonic dystrophy. , 1999, 22, 781-782.		1
240	Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutations. Neuroscience Letters, 1999, 260, 193-195.	2.1	27
241	Atypical parkinsonism in the French West Indies. Lancet, The, 1999, 354, 1474.	13.7	4
242	Neurodegenerative diseases of Guam: Analysis of TAU. Neurology, 1999, 53, 411-411.	1.1	40
243	Parkinsonism following electrical injury to the hand. Movement Disorders, 1998, 13, 600-602.	3.9	9
244	Upbeat nystagmus: clinicoanatomical correlation. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 380-381.	1.9	65
245	Early myoclonic status and outcome after cardiorespiratory arrest. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 267-268.	1.9	64
246	Sub-populations of smaller diameter trigeminal primary afferent neurons defined by expression of calcitonin gene-related peptide and the cell surface oligosaccharide recognized by monoclonal antibody LA4.. Journal of Neurocytology, 1991, 20, 716-731.	1.5	69